COMMUNIQUÉS West-GlobeNewswire

Emisphere Amends License Agreement with Novo Nordisk
26/04/2018
Emisphere to Receive $7 Million Payment ROSELAND, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB: EMIS ) today announced that it has amended its existing 2015 Development and License [...]
Progenics Pharmaceuticals Sets First Quarter 2018 Financial Results Call for May 9
26/04/2018
NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX ), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced [...]
Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer
26/04/2018
Three-arm Trial Will Evaluate CPI-006 as Monotherapy, in Combination with CPI-444 Adenosine Antagonist and in Combination with Pembrolizumab BURLINGAME, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals [...]
Agritek Holdings, Inc. Announces Purchase And Transfer Of Tier One Recreational License For Colorado On Behalf Of Approved Partner Licensee With Existing Cannabis Operations
26/04/2018
Company Expands Operations In Colorado On Heel Of New Deal With President Trump And Senator Cory Gardner Clearing Way For Colorado Medical And Recreational Cannabis LOS ANGELES, CA, April 26, 2018 (GLOBE NEWSWIRE) -- [...]
William Hartman, CEO of Premier Biomedical, Returns to Uptick Newswire’s “Stock Day” Podcast
26/04/2018
PHOENIX, April 26, 2018 (GLOBE NEWSWIRE) -- William Hartman, CEO of Premier Biomedical Inc. (OTCBB: BIEI ) ("the Company") joined Everett Jolly on Uptick Newswire’s “Stock Day” podcast to discuss recent company [...]
Alder BioPharmaceuticals® Appoints Jeremy Green to its Board of Directors
26/04/2018
BOTHELL, Wash., April 26, 2018 (GLOBE NEWSWIRE) -- Alder Biopharmaceuticals, Inc. (NASDAQ: ALDR ) (“Alder” or the “Company”), a biopharmaceutical company focused on developing novel therapeutic antibodies for the [...]
Imagin Gains Momentum; Positive Progress in Research Study
26/04/2018
VANCOUVER, British Columbia and BOSTON, April 26, 2018 (GLOBE NEWSWIRE) -- Imagin Medical (CSE:IME) (OTC PINK:IMEXF) (Frankfurt & Stuttgart Symbol:DPD2) (the “Company”) is providing the following update on the [...]
Histogenics Corporation to Report First Quarter 2018 Financial Results on May 10, 2018
26/04/2018
WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX ), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, [...]
Navamedic ASA: Strengthens international IP position with two new patents in the U.S.
26/04/2018
Oslo, 26 April 2018 - Navamedic ASA announced today that the United States Patent and Trademark Office has granted patents for the Sippi® base technology for using capacitance as a volume measurement and silicone oil as [...]
PolarityTE Leadership to Participate in the Symposium on Advanced Wound Care
26/04/2018
SALT LAKE CITY, April 26, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq: COOL ) today announced attendance and participation in the Symposium on Advanced Wound Care Spring (SAWC Spring) Wound Healing Society (WHS) [...]
Aino Health AB (publ): Aino Health gains representation in the United Arab Emirates
26/04/2018
April 26, 2018 Aino Health gains representation in the United Arab Emirates Aino Health has entered into an exclusive partnership agreement with Emirates Artificial Intelligence Technologies LLC. Emirates A.I. as the [...]
Achaogen Wins CARB-X Funding Award to Advance Development of Novel Aminoglycoside to Fight Highly-Resistant Infections
26/04/2018
-- CARB-X funding to support Achaogen’s early-stage aminoglycoside program developing antibiotics for difficult to treat infections that are associated with high mortality -- -- Awarded Up to $2.4 million over appr [...]
Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
26/04/2018
Preliminary Safety and Efficacy Data from Phase 1b/2a Trial of RX-5902 in Advanced Triple Negative Breast Cancer Updated Safety and Efficacy Data on RX-3117 in Advanced Urothelial (Bladder) Cancer ROCKVILLE, Md., April [...]
PositiveID’s Chairman and CEO Addresses Stockholders
26/04/2018
DELRAY BEACH, Fla., April 26, 2018 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTC:PSIDD), a life sciences company focused on detection and diagnostics, announced today that its Chairman and [...]
Aduro Biotech Presents Early Observations From its Personalized Neoantigen-based pLADD Therapy Clinical Study at European Neoantigen Summit
26/04/2018
pLADD Therapy Found to Induce Both Innate and Adaptive Immunity BERKELEY, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq: ADRO ) today presented preliminary observations from a case study of a [...]
Tauriga Sciences Inc. Announces Cancellation of Final Remaining Back-End Convertible Debenture Held by GS Capital Partners LLC in Connection with the $105,000 Face Value 8% Convertible Debenture Dated October 17, 2017
26/04/2018
NEW YORK, NY, April 26, 2018 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), engaged in building its business through the development, distribution, and licensing of proprietary [...]
BioNovelus Receives Organic Certification for CR-10®
26/04/2018
FOR IMMEDIATE RELEASE — Phoenix, April 26, 2018 (GLOBE NEWSWIRE) -- — BioNovelus is proud to announce that its flagship product CR-10®, a non-toxic, organic fungicide has received the organic certification from Mayacert [...]
INSYS Therapeutics and University of California (UC) San Diego Center for Medicinal Cannabis Research to Collaborate on Clinical Trial
26/04/2018
Company’s pharmaceutical-grade cannabidiol (CBD) oral solution will be evaluated by UC San Diego/CMCR researchers as potential treatment for symptoms of autism PHOENIX, April 26, 2018 (GLOBE NEWSWIRE) -- NSYS [...]
Krystal Biotech Announces FDA Clearance of IND on KB103 to Begin Enrolling Patients for the Treatment of Dystrophic Epidermolysis Bullosa
26/04/2018
KB103 is the first-ever herpes simplex virus ( HSV-1) based topical gene therapy candidate engineered to produce human collagen protein to treat dystrophic epidermolysis bullosa (DEB) The planned Phase 1/2 KB103 single [...]

Pages